Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Predictive markers for anti-EGFR antibodies in colorectal cancer: the beginning of a new era

Predictive markers for anti-EGFR antibodies in colorectal cancer: the beginning of a new era Targ Oncol (2008) 3:223–225 DOI 10.1007/s11523-008-0097-2 EDITORIAL Predictive markers for anti-EGFR antibodies in colorectal cancer: the beginning of a new era Eric Van Cutsem & Sabine Tejpar Received: 2 October 2008 /Accepted: 2 October 2008 / Published online: 13 November 2008 Springer-Verlag 2008 . . . Keywords Predictive markers Colorectal cancer EGFR FISH has some predictive value, but there are still meth- Targeted therapy odological issues (e.g., cut-off, tumor heterogeneity) that prevent its routine use as a predictive marker in clinical practice [6–9]. The epidermal growth factor receptor (EGFR) is commonly Recently it has been shown that mutations of the KRAS expressed in colorectal cancer and is widely recognized as gene, which encodes a GDP/GTP-binding protein linking an important therapeutic target for this disease. The EGFR- ligand-dependent receptor activation to intracellular pathways targeting immunoglobulin IgG1 monoclonal antibody, of the EGFR signaling cascade, are a good predictive marker cetuximab, and the IgG2 monoclonal antibody, panitumu- for determining the resistance to the anti-EGFR antibodies mab, are both approved in patients with metastatic cetuximab and panitumumab. Mutation at key sites within the colorectal cancer (mCRC). Cetuximab has been shown to gene, commonly codons 12 and 13, leads to constitutive be active as http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Targeted Oncology Springer Journals

Predictive markers for anti-EGFR antibodies in colorectal cancer: the beginning of a new era

Van Cutsem, Eric; Tejpar, Sabine
Targeted Oncology , Volume 3 (4) – Nov 13, 2008
Download PDF
3 pages

Loading next page...
 
/lp/springer-journals/predictive-markers-for-anti-egfr-antibodies-in-colorectal-cancer-the-4pyK4nNPZN

References (28)

Publisher
Springer Journals
Copyright
Copyright © 2008 by Springer-Verlag
Subject
Medicine & Public Health; Biomedicine general; Oncology
ISSN
1776-2596
eISSN
1776-260X
DOI
10.1007/s11523-008-0097-2
Publisher site
See Article on Publisher Site

Abstract

Targ Oncol (2008) 3:223–225 DOI 10.1007/s11523-008-0097-2 EDITORIAL Predictive markers for anti-EGFR antibodies in colorectal cancer: the beginning of a new era Eric Van Cutsem & Sabine Tejpar Received: 2 October 2008 /Accepted: 2 October 2008 / Published online: 13 November 2008 Springer-Verlag 2008 . . . Keywords Predictive markers Colorectal cancer EGFR FISH has some predictive value, but there are still meth- Targeted therapy odological issues (e.g., cut-off, tumor heterogeneity) that prevent its routine use as a predictive marker in clinical practice [6–9]. The epidermal growth factor receptor (EGFR) is commonly Recently it has been shown that mutations of the KRAS expressed in colorectal cancer and is widely recognized as gene, which encodes a GDP/GTP-binding protein linking an important therapeutic target for this disease. The EGFR- ligand-dependent receptor activation to intracellular pathways targeting immunoglobulin IgG1 monoclonal antibody, of the EGFR signaling cascade, are a good predictive marker cetuximab, and the IgG2 monoclonal antibody, panitumu- for determining the resistance to the anti-EGFR antibodies mab, are both approved in patients with metastatic cetuximab and panitumumab. Mutation at key sites within the colorectal cancer (mCRC). Cetuximab has been shown to gene, commonly codons 12 and 13, leads to constitutive be active as

Journal

Targeted Oncology – Springer Journals

Published: Nov 13, 2008

There are no references for this article.